WO2007108108A1 - 新規ステンフォン(Stemphone)類の化合物及びその製造法 - Google Patents
新規ステンフォン(Stemphone)類の化合物及びその製造法 Download PDFInfo
- Publication number
- WO2007108108A1 WO2007108108A1 PCT/JP2006/305625 JP2006305625W WO2007108108A1 WO 2007108108 A1 WO2007108108 A1 WO 2007108108A1 JP 2006305625 W JP2006305625 W JP 2006305625W WO 2007108108 A1 WO2007108108 A1 WO 2007108108A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substance
- stenphone
- compound
- stemphone
- culture
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/02—Oxygen as only ring hetero atoms
- C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Definitions
- the present invention relates to a compound of a new stenphone (s. Temp. Ho rue.) Class which enhances its effect when used in combination with S-lactam antibiotic imipenem, which is used as an antibacterial agent, and its production Regarding the law.
- a new stenphone s. Temp. Ho rue.
- MRSA methicillin-resistant Staphylococcus aureus
- yS-lactam antibiotics drugs that are generally a glycopeptide that has not been reported to be resistant to methicillin-resistant Staphylococcus aureus (MRSA) infections.
- Antibiotics such as vancomycin-based aminoglycoside arbekacin are used.
- S-lactam antibiotics, or a combination therapy with one lactam antibiotic and another antibiotic with a different action point Yama Hasegawa et al., Science of Antimicrobial Administration, 2 6 4 — 2 7 3, 1 9 9 8).
- Conventional technology Conventional technology
- Vancomycin and arbekacin have already emerged resistant to these drugs.
- these drugs are known to have side effects such as hearing loss due to the eighth cranial nerve disorder, which is a problem.
- a tea extract or its active fraction JP-A 9-500 077 that exhibits a synergistic effect when used in combination with antibacterial agents including ST lactam antibiotics corresponds to this. Disclosure of the invention The new stenphones are clearly distinguished in molecular formula and chemical structure from polyphenol compounds, which are active ingredients in tea extract or its active fraction.
- stemphone B substance has a MIC of imipene from 16 g / ml to 0.03 g Zml, and has a 5 to 2-fold increase in activity. The increase in activity by 5 12 and 16 times was confirmed, respectively, and it is expected to be applied to a combination drug for raccoon antibiotics for methicillin-resistant Staphylococcus aureus (MR SA) infection.
- MR SA methicillin-resistant Staphylococcus aureus
- Drugs that enhance the activity of ⁇ -lactam antibiotics are expected to reduce the frequency of resistant bacteria by reducing the dose of / S-lactam antibiotics and shortening the administration period. At the same time, it is expected to overcome resistance to 8-lactum antibiotics by combining two drugs with different actions.
- the object of the present invention is to provide a substance having an action of enhancing the activity of ⁇ -lactam antibiotics against methicillin-resistant Staphylococcus aureus (MR SA), and methicillin-resistant Staphylococcus aureus (MR SA) infection or ⁇ -It is useful as a new therapeutic agent for infectious diseases caused by multidrug-resistant bacteria including resistance to lactam antibiotics.
- MR SA methicillin-resistant Staphylococcus aureus
- MR SA methicillin-resistant Staphylococcus aureus
- the present inventors examined the culture solution of the filamentous fungus FK 1-2 1 3 6 previously isolated from soil, and found that the imipene activity enhancing substance is different from the Stenphone B substance and the Stenphone C substance. Has been found to be produced. Next, three imipenem activity enhancing substances were separated and purified from the culture. Since no substance having such a chemical structure has been known at all, this substance is called Stenphone D substance, Stenphone E substance and Stenphone F substance, respectively. In addition, as for the Stenphone E substance, as a result of the preparation of derivatives, no substance having such a chemical structure has been known so far. It was decided to refer to the substance Opstenphone E 3 substance.
- the present invention also belongs to the genus Aspergillus, and the phone according to claim 1.
- a microorganism belonging to the genus Aspergillus and capable of producing a compound of a stenphone is an Aspergillus sp.
- FK I— 2 1 36 (Aspergillus sp: F I- 2136 (NITE BP-83)
- This strain grows well on the toppec 'yeast extract agar medium, wort agar medium, toppec yeast containing 20% sucrose, etc., and conidia is well established on each agar medium. .
- Optimal growth conditions The optimal growth conditions for this strain are pH 4-8 and temperature 11.5-29 ° C.
- the growth range of this strain is pH 3 to 10 and temperature 10 to 30.5 ° C.
- FK 1-21 36 Based on the morphological characteristics of the FK 1-21 36 strain described above: based on the culture characteristics and physical characteristics, as a result of comparison with known bacterial species, this strain was identified as belonging to the genus Aspergillus). Aspergillus sp. It was named FK'4—21 36. This strain is Aspergillus sp. FK I-21 36 (Aspergillus sp.
- FK I-2 1 36 substance-producing bacterium used in the present invention or the aforementioned Aspergillus sp. FK 1-21 36 strain is a preferred example.
- the properties are highly variable and are not constant.
- Natural or usual UV irradiation, X-ray irradiation or mutant derivatives such as N-methyl-N'-nitro-N-nitrosoguanidine, 2-aminopurine. It belongs to Aspergillus sp., Including the human soil mutants that use etc., and is represented by the above formulas [I], [I], [IE], [IV], [V] and [VI].
- a strain having the ability to produce a compound of the stelphones is included in the present invention.
- FK 1-2136 substance-producing bacteria are cultured in a medium.
- a nutrient source suitable for the production of the compounds of the tenphones a nutrient medium containing a carbon source that can be assimilated by microorganisms, a nitrogen source that can be digested, and inorganic salts, vitamins, and the like as required.
- Assimilable carbon above As sources glucose, fructose, maltose, lactose, galactose, saccharides such as dextrin and starch, and vegetable oils and fats such as soybean oil are used alone or in combination.
- Digestible nitrogen sources include peptone, yeast extract, meat extract, soy flour, cottonseed flour, corn steep liquor, malt extract, casein, amino acids, urea, ammonium salts, nitrates alone or nitrates Used in combination.
- Other heavy metal salts such as phosphates, magnesium salts, calcium salts, sodium salts, potassium salts, iron salts, manganese salts, copper salts, cobalt salts, zinc salts, etc.
- Mines and other compounds suitable for production of the present stenphone compounds are added as appropriate.
- an antifoaming agent such as a surfactant such as liquid paraffin, animal oil, vegetable oil, silicone, etc. may be added as necessary.
- the medium may be liquid or solid as long as it contains the above nutrient sources, but it is usually preferable to use a liquid medium for culture.
- culture using a flask is preferable.
- the composition of the medium used for the preculture and the medium used for the production culture may be the same, or may be changed if necessary.
- the culture temperature may be appropriately changed within the range in which the FK 1-21 3 6 substance-producing bacterium produces the compounds of the stemphones, but usually 20 to 30 ° C, preferably 27 ° C. It is better to incubate around C.
- the culture pH is usually 5 to 8, preferably about 7.
- the culture time varies depending on the culture conditions, but is usually about 4-7 days.
- the compounds of stenphones thus obtained are present in cultured cells and culture filtrate.
- the product is extracted with a water-miscible organic solvent such as aceton, the extract is distilled off under reduced pressure with an organic solvent, and then the residue is extracted with a water-immiscible organic solvent such as ethyl acetate.
- UV absorption spectrum measured in methanol solution is: ima x (Me ⁇ H, ⁇ ): 20 3 nm (1 7 4 4 2), 2 Absorption at 6 5 nm (8 2 8 4) and 3 96 nm (6 7 8)
- Red external absorption spectrum The infrared absorption spectrum measured by the potassium bromide tablet method is i max 3 4 4 2, 2 9 7 3, 1 7 3 5, 1 6 4 3 , 1 6 0 4 cm "shows a characteristic absorption maximum at 1 etc.
- Solubility in solvents Soluble in methanol and black form, insoluble in water
- Proton and carbon nuclear magnetic resonance spectra Hydrogen chemical shift (P Pm) and carbon chemistry measured in a heavy oxygen source with a 30 OMHz nuclear magnetic resonance spectrometer manufactured by Varian.
- the shift (p pm) is as shown below. ⁇ 0 • 8 9 (3 H), 1.0 2 (3 H), 1 • 1 5 (3 H), 1 • 2 0 (
- Stenphone D substance has a chemical structure represented by the above formula [I].
- UV absorption spectrum Measured in methanol solution UV absorption spectrum is ⁇ ma X (Me OH, ⁇ ): 20 4 nm (3 4 4 4 7), 2 9 2 Absorption at nm (4 3 7 0), 3 5 6 nm (4.0 3)
- Red external absorption spectrum Infrared absorption spectra measured by the brominated power Ryumu tablet method are: Re max 3 4 3 4, 2 9 2 9, 1 7 1 8, 1 6 2 9 cm A characteristic absorption maximum at 1 etc.
- UV absorption spectrum measured in methanol solution is: ima x (Me OH, ⁇ ): 20 2 nm (3 4 5 0 3), 29 Absorption at 1 nm (3 8 8 9) and 3 60 nm (4 2 2)
- Red external absorption spectrum Infrared absorption spectra measured by the bromide-powered Rum tablet method are max 34 3 2, 2 9 3 1, 1 727, 1 6 3 3 cm 1 etc. Shows a characteristic absorption maximum
- Proton and carbon nuclear magnetic resonance spectra Hydrogen chemical shifts (ppm) and carbon chemical shifts measured in a heavy-duty form with a Varian 300 MHz nuclear magnetic resonance spectrometer. (P pm) is as shown below.
- Stenphone E 1 substance has a chemical structure represented by the above formula [ ⁇ ]. Was decided.
- UV absorption spectrum measured in methanol solution is: ima x (Me OH, ⁇ ): 20 2 nm (3 3 5 3 3), 2 87 nm (
- Red external absorption spectrum Infrared absorption spectrum measured by the bromide-powered Rum tablet method is special for max 34 3 4, 2 975, 1 720, 1 6 3 7 cm 1 etc. The maximum absorption
- Stenphone E 2 substance has a chemical structure represented by the above formula [IV]. It has been determined.
- UV absorption spectrum measured in methanol solution is ima x (Me OH, ⁇ ): 2 Q 2 nm (1 5: 0; 1 4), 2 Absorption of 7 2 nm (1 1 4 7 8), 4 7 3 nm (2 7 4 8)
- Red external absorption spectrum Potassium bromide tablet method
- the infrared absorption spectrum measured is as follows: Les max 3 4 3 4, 2 9 2 7, 1 7 3 3, 1 6 4 8, 1 6 2 1 cm—A characteristic absorption maximum at 1 etc.
- Stenphone E 3 substance As described above, as a result of detailed examination of various physicochemical properties and spectral data of the Stenphone E 3 substance, the Stenphone E 3 substance has the chemical formula represented by the above formula [V]. Stenphone F substance determined to be structural
- UV absorption spectrum The ultraviolet absorption spectrum measured in methanol solution is: max (Me ⁇ H, ⁇ ): 2 0 1 nm (1 1 6 6 9), 2 4 4 nm (6 4 2 7), 2 8 8 nm (3 6 0 3), 3 6 1 nm (3 8 7)
- Red external absorption spectrum Infrared absorption spectra measured by the potassium bromide tablet method are: Re max 3 4 3 8, 2 9 6 7, 1 6 5 8, 1 6 2 9, 1 6 2 3 cm—shows a special absorption maximum at 1 mag
- ⁇ -ton and carbon nuclear magnetic resonance spectra hydrogen chemical shift (p pm) and carbon measured in a heavy-duty form with a 300 MHz nuclear magnetic resonance spectrometer manufactured by Varian.
- the chemical shift (ppm) is as shown below.
- ⁇ c 1 1. 1, 1 3.3, 1 3.4, 2 0.1, 2 1.5, 2 1, 8, 2 3
- Stenphone F substance has a chemical structure represented by the above formula [VI]. It has been determined.
- the smearing was performed using a sterile swab (Kawamoto Sangyo Co., Ltd., Japan) according to the US National Committee for Laboratory Standards (NCCLS) method.
- NCCLS National Committee for Laboratory Standards
- the antibacterial activity on each culture medium against the test bacteria was expressed in mm as the diameter of the circle of inhibition after 20 hours at 37 ° C by the paper disk method (thin, 6 mm: ADVA NTEC).
- any of Stenphone D substance, Stenphone E substance, Stenphone E 1 substance, Stenphone E 2 substance, Stenphone E 3 substance and Stenphone F substance in the presence of imipenem, 25 mm, 22 mm, 15 mm, 22 mm, 20 mm, and 20 mm were respectively measured. As a result, the action of enhancing the activity of imipene was confirmed. In the case of Stimphon B substance and Stenfon C substance reported by the present inventors, the inhibition circle was not measured under the same conditions, but in the presence of imipenem, Because the 20 mm and 22 mm inhibition circles were measured, the newly isolated substance was almost equal to or better than the imipene activity. It became clear to have. Cytotoxicity assessment method
- Agar slope culture medium (glycerol 0.16 (Japan, Kanto Chemical Co.), KH 2 P0 4 0. 0 8% (Japan, Kanto Chemical Co.), KH 2 P 04 0. 0. 0. 0 2% (Japan) , Seki Higashika Gakusha), MgS0 4 ⁇ 7H 2 0 0. 0 2% ( Japan, Wako Pure Chemicals), KC 1 0. 0 2% ( Japan, Kanto Chemical Co., Inc.), NaN0 3 0. 2% (Japan, Wako Pure Chemical Industries), Yeast extract 0.0 2% (Japan, Oriental Yeast), Agar 1.5%
- the culture solution (4.9 L) was centrifuged to obtain a supernatant and cells.
- Acetone 2.5 L was added to the cells and stirred for 30 minutes, and the cells were separated by filtration to obtain a cell extract.
- the aqueous extract obtained by distilling off acetone from the bacterial cell extract under reduced pressure and the above-mentioned supernatant are mixed, the active ingredient is extracted with ethyl acetate (5 L), and the ethyl acetate layer is concentrated to dryness.
- the active crude material (6.4 g) was obtained.
- the crude material was roughly purified by a silica gel column (silica gel 60, Merck, 60 g).
- ⁇ / roform monomethanol (10: 00 (10 Oml ⁇ , 100 : 20 OmL), 50: 1 (30 OmL), 10: 1 (30 OmL), 5; 1 Fractionation was performed by chromatography using each mixed solvent of (300 mL) and 1: 1 (30 OmL)) as a developing solvent.
- the active fraction (50: 1) was concentrated to dryness to obtain 70 mg of a brown oily substance.
- the crude material was purified again with a silica gel column (silica gel 60, Merck, 30 g). Black-mouthed form methanol (1 0 0: 0 (50 mL x 2), 1 0 0: 1 (3 0 mL x 5), 5 0: 1 (25 mL 10), 1 0: 1 (3 0 mL x 5 ) And 5: 1 (3 OmL ⁇ 5)) were chromatographed using a mixed solvent as a developing solvent.
- Preparative HPLC (column: PEGASIL ODS, 200 x 250 mm) 1 7 mg of methanol soluble part of crude material 3 Omg obtained by concentrating the active fraction (10: 1 fraction number 3-4) to dryness , Moving bed: 45% aqueous solution of acetonitrile, flow rate: 6m 1 Zmin, detection: UV 2 10 nm), separating peak of retention time 6 4min and concentrating the fractionated solution under reduced pressure
- the stenphone D substance was isolated in a yield of 1.2 mg.
- the active fraction (50: 1 fraction number 7-10) after the second silica gel column was concentrated to dryness to obtain a white powdered Stenphone E substance in a yield of 3 18 mg.
- 50 mg of Stenphone E substance was mixed with 170 7L of TMS-diazomethane (Nacalai Tesque, Japan), 10% hexane solution and methanol 34 After reacting in 0 ⁇ L solution at 40 ° C for 24 hours, preparative HPLC (column: PEGASIL ODS, 200 x250tnm, moving bed: 70% aqueous solution of acetonitrile, flow rate: SmLZmin, detection: UV 2 1 0 nm).
- Von E 1 material was isolated in a yield of 1 1.6 mg.
- 5 Omg of Stenphone E substance was heated in aqueous solution at 60 ° C, and then the concentrated dry solid was dissolved in a small amount of methanol, followed by preparative HPLC. Purification was performed by (column: PEGASIL ODS, 200 ⁇ 25 Omm). The absorption at UV 2 10 nm was monitored at a flow rate of 6 mL / min using isocratic of 70% aqueous acetonitrile as a moving bed. Retention times 1 4 min and 2 1 min peaks were collected, and the fractions were concentrated under reduced pressure to yield the yields of Stenphone E 2 substance and Nmphone E 3 substance, respectively. Released.
- the culture solution to (0.1 L) was centrifuged to obtain a supernatant and cells.
- Acetone (2.5 L) was added to the cells and stirred for 30 minutes, and the cells were separated by filtration to obtain a cell extract.
- the aqueous residue obtained by distilling off the acetone from the bacterial cell extract under reduced pressure and the above-mentioned supernatant were mixed, the active ingredient was extracted with ethyl acetate (0.5 L), and the ethyl acetate layer was concentrated and dried.
- Solid active crude material (0.5 g) was obtained. This crude material was roughly purified on a silica gel column (silica gel 60, Merck, 2.3 g).
- Stemphone D substance obtained by culturing a microorganism represented by FK 1-2 1 3 6 strain belonging to the genus Aspergillus having the ability to produce compounds of the novel stenphones of the present invention in a culture medium.
- Stenphone E substance, Stenphone E 1 substance, Stenphone E 2 substance, Stenphone E 3 substance, or Stenphone F substance are equivalent to or better than the previously reported Stenphone C substance. It is expected to be useful as a lead for concomitant medications for methicillin-resistant Staphylococcus aureus (MRSA) infections.
- MRSA methicillin-resistant Staphylococcus aureus
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2006/305625 WO2007108108A1 (ja) | 2006-03-15 | 2006-03-15 | 新規ステンフォン(Stemphone)類の化合物及びその製造法 |
US11/911,868 US7982057B2 (en) | 2006-03-15 | 2006-03-15 | Compound of stemphones and production thereof |
JP2007548254A JP5036554B2 (ja) | 2006-03-15 | 2006-03-15 | 新規ステンフォン(stemphone)類の化合物及びその製造法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2006/305625 WO2007108108A1 (ja) | 2006-03-15 | 2006-03-15 | 新規ステンフォン(Stemphone)類の化合物及びその製造法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007108108A1 true WO2007108108A1 (ja) | 2007-09-27 |
Family
ID=38522148
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/305625 WO2007108108A1 (ja) | 2006-03-15 | 2006-03-15 | 新規ステンフォン(Stemphone)類の化合物及びその製造法 |
Country Status (3)
Country | Link |
---|---|
US (1) | US7982057B2 (ja) |
JP (1) | JP5036554B2 (ja) |
WO (1) | WO2007108108A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113173904A (zh) * | 2021-03-23 | 2021-07-27 | 中国地质大学(北京) | 新的抑菌化合物以及用于制备该化合物的曲霉 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9404303D0 (en) * | 1994-03-04 | 1994-04-20 | Royal Free Hosp School Med | Antibacterial agent |
-
2006
- 2006-03-15 US US11/911,868 patent/US7982057B2/en not_active Expired - Fee Related
- 2006-03-15 JP JP2007548254A patent/JP5036554B2/ja not_active Expired - Fee Related
- 2006-03-15 WO PCT/JP2006/305625 patent/WO2007108108A1/ja active Application Filing
Non-Patent Citations (1)
Title |
---|
HUBER C. ET AL.: "Stemphone, a new type of natural quinone", TETRAHEDRON LETTERS, vol. 29, 1974, pages 2545 - 2548, XP003000070 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113173904A (zh) * | 2021-03-23 | 2021-07-27 | 中国地质大学(北京) | 新的抑菌化合物以及用于制备该化合物的曲霉 |
CN113173904B (zh) * | 2021-03-23 | 2022-07-29 | 中国地质大学(北京) | 新的抑菌化合物以及用于制备该化合物的曲霉 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2007108108A1 (ja) | 2009-07-30 |
US7982057B2 (en) | 2011-07-19 |
JP5036554B2 (ja) | 2012-09-26 |
US20090093646A1 (en) | 2009-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006075395A1 (ja) | β−ラクタム抗生物質の活性増強剤及びその製造法 | |
JPH06157582A (ja) | 抗真菌性物質be−31405 | |
WO2007108108A1 (ja) | 新規ステンフォン(Stemphone)類の化合物及びその製造法 | |
JPH01193265A (ja) | 新規抗腫瘍性抗生物質sf2587物質及びその製造法 | |
JP5144167B2 (ja) | 新規kb−3346−5物質およびその製造方法 | |
WO2010122669A1 (ja) | 新規化合物アミコラマイシン、その製造方法及びその用途 | |
KR101492206B1 (ko) | 하이드록시 지방산의 글리세롤유도체 및 그 제조방법 | |
JP3902530B2 (ja) | 新規抗生物質キガマイシン類とその用途 | |
JP5030777B2 (ja) | 生理活性物質nk13650p3、その製造法及び用途 | |
JPWO2006095444A1 (ja) | ステンフォン(stemphone)類およびそれらの製造方法 | |
JPH05155888A (ja) | 新規な抗生物質およびそれらの製造 | |
JP3517880B2 (ja) | 抗真菌性物質be−49385類及びその製造法 | |
JP4585644B2 (ja) | 新規物質pf1223およびその製造法 | |
JP2004203783A (ja) | 抗菌性化合物およびその製造法 | |
WO1998041503A1 (fr) | Substance physiologiquement active pf1191 et procede de production de cette derniere | |
JP2000086627A (ja) | 抗菌性物質be−54476及びその製造法 | |
JP5163168B2 (ja) | 新規fki−3864物質およびその製造方法 | |
JP2005218320A (ja) | 新規抗真菌物質fa424a(n)、fa424a(o)、fa424b、及びfa424d | |
JPS63192792A (ja) | 新規抗生物質sf2487物質及びその製造法 | |
WO2011111738A1 (ja) | 新規fki-4429物質およびその製造方法 | |
JPS62275687A (ja) | Yp−02259l−aおよびc物質並びにその製法 | |
JPH09194497A (ja) | 抗菌性物質be−53594類及びその製造法 | |
WO2004033703A1 (ja) | 新規マクロファージ泡沫化阻害物質fka−25およびその製造法 | |
JPH04120087A (ja) | 新規抗腫瘍性抗生物質sf2587c物質およびその製造法 | |
JPH10114778A (ja) | 新規化合物f−12517 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2007548254 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06729592 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11911868 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06729592 Country of ref document: EP Kind code of ref document: A1 |